We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

433 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 127 increasing their positions, 101 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 60

60% more capital invested

Capital invested by funds: $2.2B → $3.52B (+$1.32B)

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

26% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 101

9% more funds holding

Funds holding: 396 → 433 (+37)

8.4% more ownership

Funds ownership: 75.39% → 83.79% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
433
Holders Change
+37
Holders Change %
+9.34%
% of All Funds
5.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
101
Increased
127
Reduced
101
Closed
60
Calls
$244M
Puts
$186M
Net Calls
+$58.2M
Net Calls Change
+$37.5M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$134M
2
OAG
Orbis Allan Gray
Bermuda
+$46.5M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.7M
4
State Street
State Street
Massachusetts
+$33.3M
5
UBS Group
UBS Group
Switzerland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$38.2M
2
Morgan Stanley
Morgan Stanley
New York
-$30.5M
3
BBA
Baker Bros. Advisors
New York
-$22.3M
4
Millennium Management
Millennium Management
New York
-$19.9M
5
Capital International Investors
Capital International Investors
California
-$18.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
HKAM
176
Horizon Kinetics Asset Management
New York
$498K -$17.1K -443 -4%
CWM
177
CIBC World Markets
New York
$496K +$395K +10,199 New
NFG
178
Norris Financial Group
South Carolina
$473K +$1.86K +48 +0.5%
WF
179
WinCap Financial
Massachusetts
$452K +$1.86K +48 +0.5%
SA
180
Sanctuary Advisors
Indiana
$442K +$17.8K +460 +5%
FIM
181
Freedom Investment Management
Connecticut
$438K -$19.6K -506 -5%
OC
182
Oppenheimer & Co
New York
$437K -$19.2K -495 -5%
Public Employees Retirement Association of Colorado
183
Public Employees Retirement Association of Colorado
Colorado
$436K – – –
WC
184
Wexford Capital
Florida
$433K +$345K +8,906 New
Kovitz Investment Group Partners
185
Kovitz Investment Group Partners
Illinois
$431K +$343K +8,855 New
JWM
186
Jupiter Wealth Management
Colorado
$430K – – –
NA
187
NewEdge Advisors
Louisiana
$417K +$201K +5,205 +154%
SW
188
SteelPeak Wealth
California
$416K -$12.3K -318 -4%
AWCI
189
Alpine Woods Capital Investors
New York
$413K +$71.6K +1,851 +28%
AIP
190
Ameritas Investment Partners
Nebraska
$411K +$327K +8,451 New
BCI
191
Brinker Capital Investments
Pennsylvania
$395K +$314K +8,117 New
FFA
192
Farther Finance Advisors
California
$394K +$95.5K +2,467 +44%
HT
193
Headlands Technologies
Illinois
$394K +$313K +8,092 New
SS
194
SBI Securities
Japan
$376K -$9.33K -241 -3%
IAA
195
Independent Advisor Alliance
North Carolina
$375K -$9.33K -241 -3%
BFIC
196
Bedell Frazier Investment Counselling
California
$372K -$275K -7,118 -48%
Franklin Resources
197
Franklin Resources
California
$370K +$6.38K +165 +2%
QCM
198
Qsemble Capital Management
New York
$369K +$293K +7,581 New
JRP
199
Jasper Ridge Partners
California
$363K – – –
BPA
200
Beacon Pointe Advisors
California
$362K +$288K +7,446 New
6 7
8
9 10

CRSP Hedge Fund Activity: Q2 2025 in Review

433 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CRSP positions and 60 closed out — a net gain of 41 holders — while 127 added to existing stakes and 101 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 433 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 396 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 101 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +41 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.